BioLine Rebounds as Trial Lifts Outlook: Israel OvernightLeslie Picker
BioLineRX Ltd. is rebounding from a record low after the Israeli drugmaker’s leukemia treatment was approved for a second round of testing in the U.S., bolstering a company that hasn’t turned a profit since 2010.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Puerto Rico Faces Hurricane Maria After Irma’s $1 Billion Damage
- The World’s Biggest Wealth Fund Hits $1 Trillion
- Finland’s Welfare State Has a Massive Baby Problem
- Equifax Suffered a Hack Almost Five Months Earlier Than the Date It Disclosed
- Toys ‘R’ Us Collapses Into Bankruptcy Thanks to Crushing Debt